Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma

Cancer

Volumn 91, Issue 11, 2001, Pages 2033-2038

  Louvet, Christophe ^a   De Gramont, Aimery ^a   Tournigand, Christophe ^a   Artru, Pascal ^a   Maindrault Goebel, Frédérique ^a   Krulik, Marcel ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Advanced colorectal carcinoma; Chemotherapy; Endpoint measures; Progression free survival; Response rate

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CISPLATIN; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; RALTITREXED; TEGAFUR; TRIMETREXATE; URACIL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CARCINOMA; CORRELATION FUNCTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS;

EID: 0035371228     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J     Document Type: Article

References (43)

1. Hayward JL, Rubens RD, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
3. World Health Organization. WHO handbook for reporting results of cancer treatment (WHO offset publication 48). Geneva: World Health Organization, 1979.
4. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-8.
5. Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med 1996;15:2797-812.
6. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
7. Graf W, Påhlman L, Bergström R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994;70: 559-63.
8. Graf W, Bergström R, Påhlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994;30A:453-57.
9. Markman M. Why does a higher response rate to chemotherapy correlate poorly with improved survival? J Cancer Res Clin Oncol 1993;119:700-1.
10. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1992;10:896-903.
11. A'hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988;57:615-8.
12. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
13. Gustafson P. A Bayesian analysis of bivariate survival data from a multicentre cancer clinical trial. Stat Med 1995;14: 2523-35.
14. Gray RJ. A kernel method for incorporation information on disease progression in the analysis of survival. Biometrika 1994;81:527-39.
15. Bajetta F, Colleoni M, Rosso R, Sobrero A, Amadori D, Comelia G, et al. Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993;29A:1658-63.
16. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal carcinoma. J Clin Oncol 2000;18:2938-47.
17. Price T, Cunningham D, Hickish T, Tait D, Norman A, Ross PJ, at al. Phase III study of chronomodulated vs protracted venous infusional 5-fluorouracil both combined with mitomycin in first-line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1999;18:262a.
18. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-47.
19. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjödén P-O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994;73:556-62.
20. Poon MA, O'Connell MJ, Wieand HS, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
21. Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, et al. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993;11:1888-93.
22. Buroker TR, O'Connell MJ, Wieand S, Krook JE, Gestner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
23. Greco FA, Figlin RA, York M, Einhorn L, Schilsky R, Marshall EM, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996;14:2.
24. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A 3rd, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-74.
25. Jäger E, Heike M, Klein O, Bernhard H, Lautz D, Michaelis J, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 1996;14:2274-9.
26. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996;7:961-5.
27. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. A randomized trial comparing monthly with low-dose leucovorin-fluorouracil bolus with biomonthly high-dose leucovorin-flourouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997;15(2):808-15.
28. Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, et al. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the 1-isomer of intranveous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997;15(11): 3320-9.
29. Labianca R, Cascinu S, Frontini L, Barni S, Fiorentini G, Cornelia G, et al. High-versus low-dose leve-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a "GISCAD" phase III study: Italian Group for the Study of Digestive Tract Cancer. Ann Oncol 1997;8(2):169-74.
30. Pazdur R, Vincent M. Ralitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer (ACC): results of randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997; 16:228a.
31. Scheithauer W, Kornek G, Marczell A, Salem G, Karner J, Kovats E, et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 1997;15:908-91.
32. Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, et al. The impact of adding low-dose leucovorin to montly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Ann Oncol 1998;9:535-41.
33. Aranda E, Diaz-Rubio E, Cervantes A, Anton-Torres A, Carrato A, Massuti T, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD) study. Ann Oncol 1998;9(7):727-31.
34. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Opoen, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16(9):2943-52.
35. Sobrero A, Frassineti GL, Giulani R, Caroti C, Ravaioli A, Lanfranco C, et al. Randomized comparison between sequential methotrexate, fluorouracil and schedule-specific biochemical modulation in advanced colorectal cancer. Ann Oncol 1998;9(suppl)4:33.
36. Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, et al. Randomized comparative study or Orzel (oral Uracil/Tegafur) plus leucovorin (LV) versus parental 5-fluorouracil plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:264a.
37. Cox JV, Pazdur R, Thibault A, Maroun J, Weaver C, Jahn MW, et al. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:265a.
38. Maughan TS, James RD, Ken D, McArdle C, Lederman JA, Seymour M, et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:262a.
39. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:263a.
40. Punt CJA, Keizer HJ, Dourma J, Schuller J, Skovsgaard T, ten Napel CHH, et al. Multicenter randomized trial of 5-fluorouracil and leucovorin with or without trimetrexate as first line treatment in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1999;18:262a.
41. Twelves C, Harper P, van Cutsem E, Thibault A, Shelygin YA, Burger HU, et al. A phase III of Xeloda (capectabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a.
42. Saltz LB, Cox JV, Blanke C, Rosen LS, Feherenbacher L, Moore MI, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000;28:343(13):905-14.
43. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karesek P, et al. Irinotecam combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;25:355(9209):1401-7.